Creating a Clear Leader

in Physician Solutions

Presentation to Analysts

March 18, 2008

EXHIBIT 99.6

A Clear Leader in Physician Solutions

2

Forward Looking Statements

This communication contains forward-looking statements.  Those forward-looking statements include all

statements other than those made solely with respect to historical fact.  Forward-looking statements may

be identified by words such as “believes”, “expects”, “anticipates”, “estimates”, “projects”, “intends”,

“should”, “seeks”, “future”, continue”, or the negative of such terms, or other comparable terminology. 

Such statements include, but are not limited to, statements about the expected benefits of the transaction

involving Allscripts, MHS and Misys, including potential synergies and cost savings, future financial and

operating results, and the combined company’s plans and objectives.  In addition, statements made in this

communication about anticipated financial results, future operational improvements and results or

regulatory approvals are also forward-looking statements. Such forward-looking statements are subject to

numerous risks, uncertainties, assumptions and other factors that are difficult to predict and that could

cause actual results to vary materially from those expressed in or indicated by them. Factors that could

cause actual results to differ materially include, but are not limited to: (1) the occurrence of any event,

development, change or other circumstances that could give rise to the termination of the merger

agreement; (2) the outcome of any legal proceedings that have been or may be instituted against

Allscripts, Misys or MHS and others following announcement of entering into the merger agreement; (3)

the inability to complete the proposed transaction due to the failure to obtain stockholder or shareholder

approval

or

the

failure

of

any

party

to

satisfy

other

conditions

to

completion

of

the

proposed

transaction,

including

the

expiration

of

the

waiting

period

under

the

Hart-Scott-Rodino

Antitrust

Improvements

Act

of

1976, as amended, and the receipt of other required regulatory approvals; (4) risks that the proposed

transaction disrupts current plans and operations and potential difficulties in employee retention as a result

of the merger; (5) the ability to recognize the benefits of the merger; (6) legislative, regulatory and

economic developments; and (7) other factors described in filings with the SEC. Many of the factors that

will

determine

the

outcome

of

the

subject

matter

of

this

communication

are

beyond

Allscripts’,

Misys’

and

MHS’

ability to control or predict.  Allscripts can give no assurance that any of the transactions related to

the merger will be completed or that the conditions to the merger will be satisfied.  Allscripts undertakes no

obligation to revise or update any forward-looking statement, or to make any other forward-looking

statements, whether as a result of new information, future events or otherwise.  Allscripts is not

responsible for updating the information contained in this communication beyond the published date, or for

changes made to this communication by wire services or Internet service providers.

A Clear Leader in Physician Solutions

3

Additional Information and Where to Find It

This communication is being made in respect of the proposed business combination involving Allscripts,

Inc. (“Allscripts”) and Misys Healthcare Systems LLC (“MHS”), a wholly owned subsidiary of Misys plc

(“Misys”). In connection with this proposed transaction, Allscripts intends to file with the Securities and

Exchange Commission (the “SEC”) a preliminary proxy statement, a definitive proxy statement and other

related materials, and Misys intends to file a shareholder circular with the Financial Services Authority in

the United Kingdom. The definitive proxy statement will be mailed to the stockholders of Allscripts, and

the shareholder circular will be mailed to the shareholders of Misys.  BEFORE MAKING ANY DECISION

WITH

RESPECT

TO

THE

PROPOSED

TRANSACTION,

INVESTORS

AND

SECURITY

HOLDERS

AR

E URGED TO READ THESE DOCUMENTS AND OTHER RELEVANT MATERIALS WHEN THEY

BECOME AVAILABLE, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE

COMPANY AND THE PROPOSED TRANSACTION. Investors and security holders can obtain copies of

Allscripts’

materials (and all other offer documents filed with the SEC) when available, at no charge on the

SEC’s

website:

www.sec.gov.

Copies

can

also

be

obtained

at

no

charge

by

directing

a

request

for

such

materials

to Allscripts at 222 Merchandise Mart Plaza, Suite 2024, Chicago, Illinois 60654, Attention: Lee

Shapiro, Secretary, or to Misys at 125 Kensington High Street, London W8 5SF, United Kingdom,

Attention: Group General Counsel & Company Secretary. Investors and security holders may also read

and copy any reports, statements and other information filed by Allscripts with the SEC, at the SEC public

reference room at 100 F Street, N.E., Washington, D.C. 20549.  Please call the SEC at 1-800-SEC-0330

or

visit

the

SEC’s

website

for

further

information

on

its

public

reference

room.

Allscripts’

directors,

executive

officers

and

other

members

of

management

and

employees

may,

under

the

rules

of

the

SEC,

be

deemed

to

be

participants

in

the

solicitation

of

proxies

from

the

stockholders

of

Allscripts

in

favor

of

th

e proposed transaction.  Information about Allscripts, its directors and its executive officers, and their

ownership

of

Allscripts’

securities,

is

set

forth

in

its

proxy

statement

for

the

2007

Annual

Meeting

of

Stockholders of the Company, which was filed with the SEC on April 30, 2007.  Additional information

regarding the interests of those persons may be obtained by reading the proxy statement and other

relevant materials to be filed with the SEC when they become available.

A Clear Leader in Physician Solutions

4

Agenda

Jim Malone, CFO of Misys plc

Misys Financials

Bill Davis, CFO of Allscripts

CFO designate of Allscripts-Misys

Synergies and

Allscripts-Misys Financials

Glen Tullman, CEO of Allscripts

CEO designate of Allscripts-Misys

Allscripts-Misys:

A Clear Leader

Mike Lawrie, CEO of Misys plc

Executive Chairman designate of

Allscripts-Misys

Strategy Overview :

A Transformational Deal

A Clear Leader in Physician Solutions

5

5

About Misys

•

4,500 Employees Serving 120 Countries

•

£470m ($902m)

in Revenue (Fiscal 2007) –

Misys plc

•

LSE: MSY

•

Market Leader in Banking and Treasury and Capital markets

worldwide with over 1,200 banks and financial institutions

•

Significant Market Presence in Healthcare

–

Practice Management

–

Claims Management

–

Electronic Health Records

–

110,000 Physicians

–

£196m ($376m)

in Revenue (Fiscal 2007) –

Misys Healthcare

A Clear Leader in Physician Solutions

6

Transforming Misys: The Turnaround 

•

Restructured the business

–

Rebalanced portfolio and aligned the asset base to the strategy and higher

growth market segments

–

Costs taken out to drive reinvestment and margin improvement

•

Focused on building a platform for growth

–

Building Global service business

–

Focusing on emerging markets: China, India, Middle East and Africa

–

Created Go to Market alliances with world-class partners; Digital China, HCL,

Wipro and SAP

•

Change driven by new and deeply experienced management team

•

Progress being made on the turnaround; operational improvements,

positive revenue growth, profit growth and development milestones

A Clear Leader in Physician Solutions

7

A Transformational Deal

•

Misys and Allscripts will each combine  their respective

healthcare businesses into Allscripts-Misys

•

Misys will also transfer £165m ($330m) in cash to Allscripts-

Misys resulting in a 54.5% ownership interest (on a fully diluted

basis) for Misys in Allscripts-Misys

•

Allscripts shareholders will receive a special dividend of $330m

•

Cash will be financed by new banking facilities and a placing

underwritten by ValueAct Capital Management LLC

•

Allscripts-Misys Healthcare will be quoted on the NASDAQ

•

Misys plc will remain quoted on the LSE

A Clear Leader in Physician Solutions

8

A Clear Leader in Physician IT Solutions

•

“The perfect match in the perfect market”: Top rated

EHR + market share leader for PM in the growing

small/mid-sized physician group market

•

Highly rated, innovative products in every market

segment in which we compete (small/mid/large)

•

Experienced and proven management team

•

Creates revenue/cost synergies and near-term value

accretion for Allscripts-Misys

•

High recurring revenue visibility and strong potential

profit growth

•

Strong growth potential in a growing market

A clear leader in clinical software, information and connectivity solutions

A Clear Leader in Physician Solutions

9

Positioned to Capture the Healthcare Opportunity

•

Convergence of healthcare and technology in U.S.

•

Allscripts-Misys positioned to monetize $5 billion EHR market opportunity

•

Allscripts-Misys will:

–

Focus on presenting its enlarged customer base with a leading-edge

portfolio of products and services

–

Help streamline healthcare delivery through the innovative deployment of

IT and integrated solutions

–

Continue to support all the existing products from both companies, while

offering customers access to an enhanced portfolio including the

new

innovative MyWay EHR solution

Allscripts-Misys will be positioned to capitalize on the

transformation of U.S. Healthcare

A Clear Leader in Physician Solutions

10

Allscripts-Misys: A Clear Leader

Glen Tullman, CEO of Allscripts

CEO designate of Allscripts-Misys

A Clear Leader in Physician Solutions

11

11

A Vision…

Every day in the U.S.

approximately

150,000

physicians

*

will log on to a screen

that says

“Allscripts-Misys”

* Allscripts and Misys Estimates

A Clear Leader in Physician Solutions

12

12

About Allscripts

•

1,150+ Employees

•

$280m in Revenue (2007)

•

Nasdaq: MDRX

•

40,000+ Physicians and 700+ Hospitals

•

Established Leader in Healthcare IT Market

–

Electronic Health Records

–

Practice Management

–

e-Prescribing

–

Document Imaging

–

Personal Health Records

–

Connectivity Solutions

–

Emergency Department Information System

–

Case Management

A Clear Leader in Physician Solutions

13

Why the Physician Market?

Traditional View

Healthcare Revolves Around

the Hospital

Our View

Healthcare Revolves Around

the Physician

A Clear Leader in Physician Solutions

14

Today’s Physician IT Market –

An

Opportunity

Clinical /

Electronic

Health Records

•

The Market…

–

Highly fragmented market with over 300 participants

–

Historically divided between core practice management and clinical vendors

–

Paradigm shift to complex clinical system driving IT decisions and

consolidation in the ambulatory markets

•

Allscripts-Misys…

–

A footprint of approximately 150,000 physicians

–

A complete portfolio of integrated solutions, products and services

Core Practice

Management

Epic

GE

NextGen

Sage

eCw

A Clear Leader in Physician Solutions

15

A Proven Approach…

Practice Management System

Electronic Health Record

Installed Base (2008) = 113,000 MDs

Primarily in Small-Mid Sized Practices

2001:

Allscripts Gained Exclusive

Partnership to Market Allscripts

EHR to IDX PM Base

2008:

Allscripts Gains Exclusive

Opportunity to Market Allscripts

EHR to Misys PM Base

Installed Base (2001) = 138,000

MDs Primarily in Larger Practices

A Clear Leader in Physician Solutions

16

Market Opportunity

–

~ 500,000 U.S. Practicing Physicians

–

x          80% EHR Market Opportunity

–

x  ~$12,000 Initial Investment/Physician

–

= ~$5 Billion Opportunity

Electronic Health Record (EHR) Market = ~ $5 Billion

Practice Management (PM) Market = ~ $1 Billion/Yr.

~10% to 20% of PM Systems Replaced/Yr.

Software Maintenance Agreement (SMA) = ~ $1 Billion/Yr.

Transactions = ~

$1 to 2 Billion/Yr.

American Presidential candidates see technology as the answer to

a

better healthcare delivery system

A Clear Leader in Physician Solutions

17

The Market Segments in Which We Compete

Large Practices/

AMCs/Hospitals

25<

200 MDs

Mid-Sized

Practices

10<

24 MDs

Small Practices

1<10 MDs

Key:

Limited Presence

Leader

EHR

Practice Mgmt.

e-Prescribing

Connectivity

Solutions

Allscripts

Misys

Allscripts-

Misys

Source: Allscripts and Misys Assessment

A Clear Leader in Physician Solutions

18

The Largest Client Footprint in the U.S.

Misys

110,000 Physicians, 18,000 Medical Practices, 600 Homecare Agencies

Allscripts

A Clear Leader in Physician Solutions

19

The Largest Client Footprint in the U.S.

Allscripts-Misys

Approximately 150,000 Physicians and 700+ Hospitals Across the U.S.

A Clear Leader in Physician Solutions

20

Compelling Strategic Rationale

•

Covers approximately 1 out of 3 of all physicians in America*

•

Brings together leaders in PM and EHR

•

Ability to network across healthcare from the emergency

department to the ambulatory settings

•

Large installed base to sell leading EHR and other products into

•

Ability to help drive industry and technical standards for

functionality and interoperability

•

Creates a “hub”

from which we can sell into an existing Misys PM

base, similar to the successful IDX strategy

Leader in

EHR and PM

Highly

Complementary

Businesses

•

Significant opportunity for revenue and cost synergies through

cross-selling and rationalisation of overlapping functions

•

Drives long-term top and bottom line growth

•

Stability through a high percentage of recurring revenue

Powerful

Strategic

Financial

Rationale

* Allscripts and Misys Estimates

A Clear Leader in Physician Solutions

21

Creates a Clear Leader: Allscripts-Misys

A clear leader in clinical software, information and

connectivity solutions that empower physicians to

deliver healthcare safely, efficiently and effectively

+

A Clear Leader in Physician Solutions

22

Allscripts-Misys financials

Bill Davis, CFO of Allscripts

CFO designate of Allscripts-Misys

A Clear Leader in Physician Solutions

23

Transaction Summary

Allscripts-Misys Healthcare

Company Name

Four to Six Months

Expected Closing

$330m Cash (approximately $4.90 per share)

Retain their Shares in MDRX

NASDAQ listing maintained

Allscripts

Shareholders

Receive

Misys plc: 54.5%

Allscripts: 45.5%

Pro Forma

Ownership

Glen

Tullman

-

CEO

designate

Bill Davis -

CFO designate

Mike Lawrie -

Executive Chairman designate

Management

Allscripts to Merge with Misys Healthcare

Misys to pay $330m

Structure

Fully diluted shares

A Clear Leader in Physician Solutions

24

Allscripts shareholders receive approximately $4.90 per share in

cash and 45.5%

ownership position in Allscripts-Misys

Annual cost synergies $15-$20m expected in first year following transaction close

Allscripts-Misys Long-Term Growth Profile

Low double digit top line growth

Better visibility and higher percentage of stable, recurring revenue

Up to $25m to $30m in annual cost savings within three years

Revenue synergies from cross-selling to respective install bases

Increased operating leverage expected to result in mid-teens EPS growth

Value Creation

A Clear Leader in Physician Solutions

25

Significant and Realizable Synergy Opportunity

Cost synergies of $15m to $20m

expected in first year following

transaction close

Up to $25m to $30m in annual cost

savings within the next few years

Main drivers of cost synergies

include: Overhead, R&D, Marketing,

Administrative Functions

Revenue synergies expected from cross-

selling into respective client bases

Increased operating leverage expected to

result in mid teens EPS growth

Projected Cost Synergies

0

5

10

15

20

25

30

First Year

Run Rate

$15 -

$20 million

$25 -

$30 million

A Clear Leader in Physician Solutions

26

Receive US antitrust clearance

Complete the carve-out financial audits

File the US proxy

Distribute the shareholder circular for Misys plc shareholders

Shareholder vote from both Misys plc and Allscripts shareholders

Significant transaction costs will be recognized by Allscripts in Q1

Expected to close in four to six months

Roadmap to Completion

A Clear Leader in Physician Solutions

27

Misys Financials

Jim Malone, CFO of Misys plc

A Clear Leader in Physician Solutions

28

Transaction Overview

•

Misys and Allscripts will each combine  their respective healthcare businesses into

Allscripts-Misys which will be listed on NASDAQ

•

Misys will also transfer £165m ($330m) in cash to Allscripts-Misys resulting in a 54.5%

ownership interest (on a fully diluted basis) for Misys in Allscripts-Misys

•

Allscripts shareholders will receive a special dividend of $330m

•

Mike Lawrie will become Executive Chairman of Allscripts-Misys in addition to his role

as CEO of Misys. Glen Tullman, CEO of Allscripts, will become CEO of Allscripts-Misys.

•

Expected to generate both revenue and cost synergies

•

Expected to be earnings accretive for Misys in the first full financial year post

completion

•

Completion expected Q3 2008, subject to the approval of shareholders of both Misys

and Allscripts and customary regulatory approvals

•

Misys will continue to own 100% of its Banking division and the enlarged Misys group

will continue to be listed on the London Stock Exchange

A Clear Leader in Physician Solutions

29

Misys Financial Model

Mid-point of

End of

Turnaround

Turnaround

FY 2009-10

FY 2011-12+

March 2007 –

Strategy Presentation

Group Revenue (growth)

2-4%

4-6+%

Operating Margin, %

15-18%

18-20%+

March 2008

Group Revenue (growth)

7-9%

8-10%

Operating Margin, %

18-20%

20-22%+

Misys is now a growth company

A Clear Leader in Physician Solutions

30

Financing

Equity financing at 175p

•

Full backstop equity commitment by ValueAct

•

If ValueAct

is issued with this entire amount,

its shareholding in Misys will increase from

19.4% to 25.8%

•

Market rates

•

Unsecured, 5 year maturity

•

Expected drawdown at 

completion of $25m

•

LIBOR market rate

•

Unsecured, 5 year term

•

No prepay penalty

•

Misys issued share capital to increase from

503.5m to 546.4m (excluding treasury shares)

Pro forma debt ratios

–Leveraged on Banking and TCM

–Net Debt/2007 EBITDA of 2x

–2007 Interest Cover of 11.7x;;;

Debt Facilities -

$305M

$150M Equity

$150M Revolver

$155M Term Debt

Substantial Headroom

A Clear Leader in Physician Solutions

31

Dividends

•

Misys evolves to a growth company

•

Misys expects to pay its dividend for the year ended

May 2008 in September

•

Future cash flows invested in business to fuel growth

•

Dividend policy to be kept under regular review

Transformation into a Growth Company

A Clear Leader in Physician Solutions

32

Misys Capital Structure

Misys pre-transaction

Nov 2007

Capital Structure

£m

•

Shareholders equity

68

•

Cash and equivalents

31

•

Loans and overdrafts

4

•

Net (debt) / funds

27

Misys

post

transaction

–

pro

forma

Nov 2007

Capital Structure

£m

•

Shareholders equity

198 

•

Cash and equivalents

41

•

Loans and overdrafts

148

•

Net (debt) / funds

(108)

•

Revolving facility (new)

63

A Clear Leader in Physician Solutions

33

Governance

Shareholder Rights

•

Allscripts-Misys continues as a NASDAQ listed company

•

Misys

will

enjoy

anti-dilution

rights

that

will

allow

Misys

to

maintain

its

majority control

•

Misys plc continues to be listed on the London Stock Exchange

Board

•

Misys will nominate 6 of 10 directors on the Allscripts-Misys Board

•

Mike Lawrie will be Executive Chairman

Operations

•

Allscripts-Misys to change financial year end to 31 May

A Clear Leader in Physician Solutions

34

Current Trading and Conclusions

Mike Lawrie, CEO of Misys plc

Executive Chairman designate of Allscripts-Misys

A Clear Leader in Physician Solutions

35

Misys Group financial performance

(9 months ended 29 Feb 2008)

£22M up 35% (2007: £16M)

£70M up 5% (2007: £67M)

ILF Revenue

£54M up 29% (2007: £41M)

£163M up 8% (2007: £150M)

Total Order Intake

£15M up 166% (2007: £6M)

£51M up 52% (2007: £34M)

Operating Profit

£48M up 3% (2007: £47M)

£141M up 1% (2007: £140M)

-

Healthcare

£31M up 15% (2007:£27M)

£94M up 9% (2007: £86M)

-

TCM

£35M up 24% (2007: £28m)

£110M up 10% (2007:£100M)

-

Banking

£114M up 12% (2007: £102M)

£345M up 6% (2007:£326M)

Group Revenue

Q3

9 Months to 29 Feb ‘08

Revenue, margin and order intake are shown on a like-for-like basis

A Clear Leader in Physician Solutions

36

Q&A